1,675 reports of this reaction
3.9% of all TRAMETINIB reports
#4 most reported adverse reaction
RASH is the #4 most commonly reported adverse reaction for TRAMETINIB, manufactured by Novartis Pharmaceuticals Corporation. There are 1,675 FDA adverse event reports linking TRAMETINIB to RASH. This represents approximately 3.9% of all 42,856 adverse event reports for this drug.
Patients taking TRAMETINIB who experience rash should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
RASH is moderately reported among TRAMETINIB users, representing a notable but not dominant share of adverse events.
In addition to rash, the following adverse reactions have been reported for TRAMETINIB:
The following drugs have also been linked to rash in FDA adverse event reports:
RASH has been reported as an adverse event in 1,675 FDA reports for TRAMETINIB. This does not prove causation, but indicates an association observed in post-market surveillance data.
RASH accounts for approximately 3.9% of all adverse event reports for TRAMETINIB, making it a notable side effect.
If you experience rash while taking TRAMETINIB, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.